EUVIMEDEUVIMED entdecken
Crossref

Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study

Anne Kuijer, Kay Schreuder, Sjoerd G Elias, Carolien H Smorenburg, Emiel J T Rutgers, Sabine Siesling, Thijs van Dalen

Public Health Genomics · 2016 · 19 (5) · 276-281

DOI: 10.1159/000448278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Public Health Genomics, online erschienen am 11.08.2016. Verfasst von Anne Kuijer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Diakonessenhuis Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Estrogen, Transcriptome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer guidelines suggest the use of gene expression profiles (GEPs) in estrogen receptor-positive (ER+) breast cancer patients in whom controversy exists regarding adjuvant chemotherapy benefit based on traditional prognostic factors alone. We evaluated the current use of GEPs in these patients in the Netherlands. Patients and Methods: Primary breast cancer patients treated between January 1, 2011 and December 31, 2014 and eligible for GEP use according to the Dutch national breast cancer guideline were identified in the Netherlands Cancer Registry: ER+ patients 2 cm or grade 2 tumors 1-2 cm without overt lymph node metastases (pN0-Nmi). Mixed-effect logistic regression analysis was performed to associate characteristics of patients, tumors and hospitals with GEP use.

Results

GEPs were increasingly deployed: 12% of eligible patients received a GEP in 2011 versus 46% in 2014. Lobular versus ductal morphology (OR 0.58, 95% CI 0.47-0.72), pN1mi status (versus pN0, OR 0.52, 95% CI 0.40-0.68), and tumor size (>3 cm vs. >2 cm, OR 0.33, 95% CI 0.14-0.88) were inversely associated with GEP use. High socioeconomic status (SES) (OR 1.32, 95% CI 1.06-1.64) and younger age (OR 0.96/year increasing age, 95% CI 0.95-0.96) were positively associated with GEP use. GEP use per hospital did vary, but no predefined institutional factors remained independently associated with GEP use.

Conclusion

GEP use increased over time and was influenced by patient- and tumor-associated factors as well as by SES.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsReceptors, EstrogenTranscriptomeAdultAgedChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoplasm StagingNetherlandsPatient Care ManagementPrognosisQuality ImprovementRegistries

Substanzen

Receptors, Estrogen

Autor:innen und Institutionen

  • Department of Surgery, Diakonessenhuis Utrecht, Utrecht, The Netherlands.

Zitieren

APA

Kuijer, A., Schreuder, K., Elias, S. G., Smorenburg, C. H., Rutgers, E. J., Siesling, S., & van Dalen, T. (2016). Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study. Public Health Genomics, 19(5), 276-281. https://doi.org/10.1159/000448278

Vancouver

Kuijer A, Schreuder K, Elias SG, Smorenburg CH, Rutgers EJ, Siesling S, et al. Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study. Public Health Genomics. 2016;19(5):276-281. doi:10.1159/000448278

BibTeX
@article{Kuijer2016,
  author = {Kuijer, Anne and Schreuder, Kay and Elias, Sjoerd G and Smorenburg, Carolien H and Rutgers, Emiel J T and Siesling, Sabine and van Dalen, Thijs},
  title = {Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study},
  journal = {Public Health Genomics},
  year = {2016},
  volume = {19},
  number = {5},
  pages = {276--281},
  doi = {10.1159/000448278}
}
Kostenlos starten →